Effect of androgens combined with hormone therapy on quality of life in post-menopausal women with sexual dysfunction

Aim. To evaluate with validated instruments changes in quality of life and sexuality in women receiving hormonal replacement therapy (AHT). Design. Randomised, double-blind, double-dummy study with two parallel treatment arms. Patients and methods. Forty-seven healthy post-menopausal women, aged 45-...

Full description

Saved in:
Bibliographic Details
Published in:Gynecological endocrinology 2008-01, Vol.24 (12), p.691-695
Main Authors: Blümel, J. E., Del Pino, M., Aprikian, D., Vallejo, S., Sarrá, S., Castelo-Branco, C.
Format: Article
Language:English
Subjects:
androgen replacement therapy
Double-Blind Method
Female
hormone replacement therapy
Hormone Replacement Therapy - methods
Humans
Menopause
Methyltestosterone - administration & dosage
Middle Aged
Postmenopause
Quality of Life
Sexual Dysfunctions, Psychological - drug therapy
sexuality
Statistics, Nonparametric
Surveys and Questionnaires
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim. To evaluate with validated instruments changes in quality of life and sexuality in women receiving hormonal replacement therapy (AHT). Design. Randomised, double-blind, double-dummy study with two parallel treatment arms. Patients and methods. Forty-seven healthy post-menopausal women, aged 45-64 years, were evaluated using the Female Sexual Function Index (FSFI) and the menopause-specific quality of life questionnaire (MENQOL). Of them, 40 diagnosed with sexual dysfunction were randomised (1:1) to receive daily 0.625 mg of conjugated estrogens plus 1.25 mg of methyl-testosterone and 100 mg of micronised progesterone or placebo. After 3 months follow-up, FSFI and MENQOL questionnaires were administered for a second time. Results. Quality of life was unchanged in the placebo group whereas AHT significantly improved scores of vasomotor, psychological, physical and sexual symptoms. As expected, FSFI was not modified in the placebo group while in AHT group the FSFI score improved significantly. In addition, at the end of the study, 68.7% of subjects of the AHT group did not fit did not fit the criteria for sexual dysfunction as per the FSFI (p < 0.0001). Conclusions. Adding methyl-testosterone to hormone therapy improves quality of life and sexuality in post-menopausal women with sexual dysfunction.
ISSN:0951-3590
1473-0766
DOI:10.1080/09513590802454919